Virtual Library

Start Your Search

M. Pignata



Author of

  • +

    Poster Display Session (ID 63)

    • Event: ELCC 2017
    • Type: Poster Display Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
    • +

      137P - Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in France after a first-line platinum based therapy (ID 176)

      12:30 - 13:00  |  Author(s): M. Pignata

      • Abstract

      Background:
      Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers and has an extremely poor prognosis. Among the different histologies, squamous NSCLC represents 20 to 30% of them. Afatinib is an irreversible ErbB family blocker approved in Europe for squamous NSCLC after a first-line platinum based therapy. The objective of the present study was to evaluate the cost-effectiveness of afatinib versus erlotinib in this setting in France.

      Methods:
      The study population was taken from the LUX-Lung 8 trial which compared afatinib with erlotinib in patients with squamous NSCLC. The analysis was performed from the perspective of healthcare funders and affected patients in France. A state transition model was developed to evaluate cost-effectiveness based on progression-free survival and overall survival in the trial. Life expectancy, quality-adjusted life expectancy and direct costs were evaluated over a 10-year time horizon. Future costs and clinical benefits were discounted at 4% annually. Deterministic and probabilistic sensitivity analyses were performed.

      Results:
      Model projections indicated that patients-treated with afatinib benefitted from longer life expectancy than those treated with erlotinib (0.94 years versus 0.78 years respectively) translating to an increase of 0.094 quality-adjusted life years (QALYs). The total cost of treatment over a 10-year time horizon was higher for afatinib than erlotinib, EUR 12,364 versus EUR 9,510, leading to an incremental cost-effectiveness ratio of EUR 30,277 per QALY gained for afatinib versus erlotinib. Sensitivity analyses showed that the base case findings were stable under variation in a range of model inputs.

      Conclusions:
      Based on data from the LUX-Lung 8 trial, afatinib was projected to improve clinical outcomes versus erlotinib, with an 89% probability of being cost-effective assuming a willingness to pay of EUR 50,000 per QALY gained, following a first-line platinum based therapy for patients with squamous NSCLC in France.

      Clinical trial identification:


      Legal entity responsible for the study:
      HEVA HEOR

      Funding:
      Boehringer Ingelheim

      Disclosure:
      M. Pignata, C. McConnachie, S. Roze: The study was supported by funding from Boehringer Ingelheim. K. Le Lay: Employee of Boehringer Ingelheim. L. Luciani: Employee of Boehringer Ingelheim. J. Gordon: Employee of Boehringer Ingelheim. C. Chouaid: In the past 5 years, received fees for attending scientific meetings, speaking, organizing research or consulting from AstraZeneca, Boehringer Ingelheim, and Hoffman la Roche.